Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics
| Autor: | Cara H. Nelson, Brian Buttrick, Nina Isoherranen |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
medicine.medical_treatment
Retinoic acid Endogeny Biology Pharmacology Article Targeted therapy Xenobiotics chemistry.chemical_compound CYP26A1 Structure-Activity Relationship Cytochrome P-450 Enzyme System Psoriasis Drug Discovery medicine Animals Cytochrome P-450 Enzyme Inhibitors Humans Enzyme Inhibitors chemistry.chemical_classification Molecular Structure Cytochrome P450 General Medicine Cell cycle Retinoic Acid 4-Hydroxylase medicine.disease Enzyme chemistry biology.protein |
| Zdroj: | Current topics in medicinal chemistry. 13(12) |
| ISSN: | 1873-4294 |
| Popis: | Retinoic acid (RA), the active metabolite of vitamin A, is an important endogenous signaling molecule regulating cell cycle and maintenance of epithelia. RA isomers are also used as drugs to treat various cancers and dermatological diseases. However, the therapeutic uses of RA isomers are limited due to side effects such as teratogenicity, and resistance to treatment emerging mainly from autoinduction of RA metabolism. To improve the therapeutic usefulness of retinoids, RA metabolism blocking agents (RAMBAs) have been developed. These inhibitors generally target the cytochrome P450 (CYP) enzymes because RA clearance is predominantly mediated by P450s. Since the initial identification of inhibitors of RA metabolism, CYP26 enzymes have been characterized as the main enzymes responsible for RA clearance. This makes CYP26 enzymes an attractive target for the development of novel therapeutics for cancer and dermatological conditions. The basic principle of development of CYP26 inhibitors is that endogenous RA concentrations will be increased in the presence of a CYP26 inhibitor, thus, potentiating the activity of endogenous RA in a cell-type specific manner. This will reduce side effects compared to administration of RA and allow for more targeted therapy. In clinical trials, inhibitors of RA metabolism have been effective in treatment of psoriasis and other dermatological conditions as well as in some cancers. However, no CYP26 inhibitor has yet been approved for clinical use. This review summarizes the history of development of RAMBAs, the clinical and preclinical studies with the various structural series and the available knowledge of structure activity relationships of CYP26 inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|